BioMimetic Therapeutics, Inc. Releases Clinical Update Including Positive 52-Week Data from North American Pivotal Trial

FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics (NASDAQ: BMTI) will report today the final, one year results of its North American Pivotal Study comparing Augment Bone Graft to autograft in foot and ankle fusion surgery. The presentation of the data by Dr. Timothy Daniels, associate professor of orthopedic surgery at the University of Toronto and St. Michaels Hospital, will take place at the American Orthopaedic Foot and Ankle Society (AOFAS) summer meeting. As previously reported, the trial met its pre-specified primary endpoint of non-inferiority of Augment to autograft at six months, and the Company’s Premarket Approval (PMA) application for Augment was recently accepted by the FDA.